Elara vs. Hers for Weight Loss (2026): An Honest Comparison

Both Elara and Hers are legitimate ways for women to get a prescription GLP-1 online, and in both a licensed provider reviews you before anything is prescribed. The honest difference in 2026 comes down to focus and pricing. Elara is built around women's weight loss, prices its program all-inclusive and cash-pay, and offers both branded and compounded GLP-1s plus supporting injectables. Hers, the women's brand of Hims & Hers Health, is a broad telehealth service that, according to reporting, shifted new weight-loss patients toward branded medications after settling a patent dispute with Novo Nordisk in March 2026. Here's the fair, side-by-side picture.

Key takeaways

• Elara is women-focused and all-inclusive. Compounded semaglutide starts at $247/month and compounded tirzepatide at $355/month, a single price covering the provider visit, medication, shipping, ongoing support, and the app, with no membership fee.
• Hers is the women's brand of a large, general telehealth company (Hims & Hers). As reported, after a March 2026 settlement with Novo Nordisk, Hims & Hers stopped marketing compounded GLP-1s and moved new weight-loss patients to branded Wegovy and Ozempic. Confirm current terms directly, as offerings are still changing.
• Compounded medications are not FDA-approved. Branded Wegovy and Zepbound are FDA-approved for weight management. These are different products, we spell out the distinction below.
• Elara stacks adjuncts around the GLP-1 (B12, lipotropic, and more) and serves all 50 states plus Puerto Rico with 7-day-a-week human support.
• Neither is "better" for everyone. The right pick depends on whether you want all-in cash pricing and a women's program (Elara) or a branded-only medication through a large multi-category brand (Hers).

Is Elara or Hers better for weight loss?

It depends on what you're optimizing for. If you want transparent, all-inclusive cash pricing, a program designed around women's physiology, and the option of compounded or branded GLP-1s with supporting injectables, Elara is built for that. If you're already in the Hims & Hers ecosystem or specifically want a branded-only medication through a large, publicly traded telehealth brand, Hers may fit.

Here's how the two compare on the things that actually decide it:

Where a competitor's current price or policy isn't independently confirmed here, we've said so, check Hers directly for today's terms, because this category moved a lot in 2026.

What medications does each offer?

Elara offers the full range: branded Wegovy and Zepbound (both FDA-approved for chronic weight management), branded Ozempic and Mounjaro (FDA-approved for type 2 diabetes, their use for weight loss is off-label), plus the program's primary focus, compounded semaglutide and tirzepatide, and clinician-supervised GLP-1 microdosing. Compounded semaglutide and tirzepatide are prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you.

Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound.

Hers historically offered compounded semaglutide, but that changed in 2026. According to reporting from CNBC and STAT News, Novo Nordisk sued Hims & Hers in February 2026 over compounded copies of its semaglutide drugs, and on March 9, 2026 the two companies settled and announced a collaboration. As part of it, Hims & Hers agreed to stop selling and marketing compounded GLP-1s except where medically necessary and to offer branded Wegovy (and other Novo semaglutide products) on its platform. So as of publication, a woman starting weight-loss care with Hers is generally directed to a branded GLP-1 rather than a compounded one. Because the details are still settling, confirm the current offering with Hers before you decide.

A quick accuracy note that matters for both brands: only Wegovy and Zepbound are FDA-approved specifically for weight management. Ozempic and Mounjaro are approved for type 2 diabetes, and prescribing them for weight loss is off-label.

How do the costs of Elara and Hers compare?

The clearest way to compare is on price and what's bundled into it.

For reference, the manufacturer's list price for branded Wegovy is about $1,350 a month, per NovoCare, though most people don't pay the full sticker. Elara's compounded semaglutide starts at $247/month, all-inclusive, and drops to about $198/month on the 12-month plan; compounded tirzepatide starts at $355/month (about $298/month on the 12-month plan). Those numbers include the provider visit, the medication, shipping, ongoing access to the medical team, and the app, there is no separate membership fee, and the price doesn't climb as your dose is titrated up.

Because Hers now steers new weight-loss patients to branded medication, its pricing depends on the branded product and any platform or visit fees, and it has been reported in the range of a few hundred dollars a month for self-pay branded Wegovy in 2026. That figure moves, so verify Hers' current price directly rather than relying on a number that may be out of date. The honest comparison isn't "the same medication for less", a branded, FDA-approved drug and a compounded preparation are different products. It's a comparison of price, access, and what's included, which is why Elara publishes the whole number up front. That transparency isn't just a nicety: in December 2025, the FTC finalized an order against telehealth GLP-1 seller NextMed over undisclosed costs and membership commitments (among other deceptive practices), a reminder to check exactly what any program's price does and doesn't include.

Does Hers still offer compounded semaglutide?

As of the March 2026 settlement with Novo Nordisk, Hims & Hers agreed to stop advertising and marketing compounded GLP-1 drugs except where medically necessary, and to sell Novo's branded products instead. In practice, that means most new weight-loss patients at Hers are now offered a branded GLP-1 rather than compounded semaglutide. Whether any compounded option remains for specific medical situations is best confirmed with Hers directly, since the transition was still underway through mid-2026.

Elara, by contrast, continues to offer compounded semaglutide and tirzepatide as its primary program alongside branded options, prescribed by a licensed clinician when appropriate, with the FDA disclosure above stated plainly, not buried.

What makes Elara different for women?

A few things Elara leads with, stated without hype:

• Women-first by design. The program centers the questions women actually ask, PCOS, perimenopause and menopause, how a GLP-1 interacts with birth control, and protecting muscle during weight loss, rather than treating weight loss as a one-size product.
• Radical price transparency. One all-inclusive number, cash-pay. No insurance prior authorizations, coverage checks, or denials to fight through, and no surprise fees at checkout.
• Adjunct stacking, done honestly. Supporting options like B12 (energy and deficiency support, there's no evidence B12 causes weight loss unless you're deficient) and lipotropic injections (not FDA-approved for weight loss; evidence is limited) can be layered onto a GLP-1 when a clinician thinks they'll help. They're supporting players, not a substitute for the GLP-1.
• Real support, tools, and reach. 7-day-a-week human support, the Elara app, a private community, recipes, and workouts, included, across all 50 states plus Puerto Rico, with a licensed provider reviewing every patient.

On the medication itself, both brands work with the same molecule: in the STEP 1 trial, adults taking semaglutide 2.4 mg lost about 15% of body weight over 68 weeks, alongside diet and activity. Individual results vary, and Elara doesn't promise a number.

Safety note. GLP-1 medications carry a boxed warning for the risk of thyroid C-cell tumors and are contraindicated if you or a family member have had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other important cautions include pancreatitis, gallbladder problems, and significant gastrointestinal side effects, and GLP-1s are not recommended in pregnancy or while breastfeeding. This isn't the full list, review the FDA prescribing information and talk to a licensed provider about whether a GLP-1 is right for you.

How Elara helps

If what you want is a women's weight-loss program with one honest, all-in price, that's the whole idea behind how Elara works. Compounded semaglutide starts at $247/month and compounded tirzepatide at $355/month, all-inclusive, visit, medication, shipping, ongoing support, and the app, with no membership fee. A licensed provider reviews every patient, and support is available 7 days a week.

**Explore Elara's compounded semaglutide program from $247/month, all-in, or compounded tirzepatide from $355/month.** Not sure where to start? Take the free eligibility check, a licensed provider reviews every patient. Compounded medications are not FDA-approved.

Comparing more options? See how Elara stacks up in Elara vs. Ro, Elara vs. Mochi vs. Noom, and Elara vs. ElaraMD (a separate, similarly named company), or dig into the full semaglutide cost breakdown.

Frequently asked questions

Is Elara or Hers better for weight loss? Neither is better for everyone. Elara is women-focused with all-inclusive cash pricing and both compounded and branded GLP-1s plus adjuncts. Hers is the women's brand of a large, multi-category telehealth company that, as reported, now offers branded GLP-1s after its 2026 Novo Nordisk settlement. Pick based on pricing model and focus.

How do the costs of Elara and Hers compare? Elara publishes all-in prices: compounded semaglutide from $247/month and tirzepatide from $355/month, covering the visit, medication, shipping, support, and app. Hers now prices around a branded GLP-1 plus any separate fees, which varies, verify Hers' current terms directly. Branded Wegovy's list price is about $1,350/month per NovoCare.

Does Hers still offer compounded semaglutide? As of its March 2026 settlement with Novo Nordisk, Hims & Hers agreed to stop marketing compounded GLP-1s except where medically necessary and to sell branded medications instead, according to reporting from CNBC and STAT News. Most new weight-loss patients are now directed to a branded GLP-1. Confirm the current offering with Hers.

What makes Elara different? Elara is designed around women's weight loss, prices its program all-inclusive and cash-pay, offers compounded and branded GLP-1s plus supporting injectables, and includes 7-day support and an app. It serves all 50 states plus Puerto Rico, and a licensed provider reviews every patient. Compounded medications are not FDA-approved.

Which is better for women? Both serve women, but Elara is built specifically around female physiology, PCOS, perimenopause and menopause, birth-control interactions, and muscle preservation, rather than as one category within a broad telehealth brand. If a women-first program with transparent all-in pricing matters to you, that's Elara's focus. Talk to a licensed provider about what fits your health.

The bottom line

Elara and Hers are both legitimate telehealth routes to a prescription GLP-1, but they're built differently: Elara is a women-focused program with transparent, all-inclusive cash pricing and both compounded and branded options, while Hers is the women's brand of a large multi-category company that shifted to branded GLP-1s after its 2026 Novo Nordisk settlement. Compounded medications are not FDA-approved, and offerings are still changing, verify current terms and talk to a licensed provider about what's right for you.

References

1. NovoCare. Wegovy (semaglutide) Cost, Coverage & Savings Resources. https://www.novocare.com/patient/medicines/wegovy.html
2. CNBC. Novo Nordisk ends legal proceedings against Hims & Hers over compounded weight loss drugs (Mar. 9, 2026). https://www.cnbc.com/2026/03/09/novo-nordisk-ends-legal-proceedings-hims-hers-compounded-weight-loss-drugs.html
3. STAT News. Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales (Mar. 9, 2026). https://www.statnews.com/2026/03/09/novo-nordisk-wegovy-hims-hers-deal/
4. U.S. Food & Drug Administration / DailyMed. Wegovy (semaglutide) Prescribing Information, Boxed Warning: Risk of Thyroid C-Cell Tumors. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
5. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
6. Federal Trade Commission. FTC Approves Final Order Against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs (Dec. 3, 2025). https://www.ftc.gov/news-events/news/press-releases/2025/12/ftc-approves-final-order-against-telehealth-provider-nextmed-over-charges-it-used-deceptive

This article is for general education and is not medical advice. It doesn't replace a conversation with a licensed clinician about your health, medications, or treatment. Reading it doesn't create a doctor-patient relationship. If you have a medical emergency, call 911. See our full Medical Disclaimer.

About compounded medications: Compounded semaglutide and tirzepatide are prepared by a state-licensed compounding pharmacy and prescribed by a licensed clinician when appropriate for you. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. They are not "generic" versions of Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. Talk to a licensed clinician about whether a compounded or FDA-approved option is right for you.